Protocol Research Designation & Liability

Synergistic protocols aggregated in the MinMaxMuscle archive are for experimental research only. Combining compounds increases physiological complexity and risk. These matrices are NOT medical prescriptions. Full medical consultation is required prior to any research application.

Full Disclaimer
Protocol Identifier

Aesthetic Repair

Skin & Wound Healing

Archival Status

The Aesthetic Repair protocol combines GHK-Cu (copper peptide), BPC-157, and TB-500 into a three-compound skin and tissue regeneration stack that addresses collagen synthesis, angiogenesis, and systemic soft tissue repair through distinct but complementary mechanisms. GHK-Cu (glycyl-L-histidyl-L-lysine:copper complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Its plasma concentration declines with age — from approximately 200 ng/mL at age 20 to 80 ng/mL at age 60 — correlating with the reduction in skin repair capacity observed with aging. GHK-Cu activates more than 4,000 genes, including key regulators of collagen I, III, VII, and IV synthesis, metalloproteinase (MMP) activity for extracellular matrix remodeling, anti-inflammatory cytokine expression, and VEGF-driven angiogenesis. Research demonstrates measurable improvements in skin thickness, elasticity, wrinkle depth, and wound healing rate in clinical studies. Topical application penetrates the dermis; subcutaneous administration provides systemic distribution. BPC-157 contributes angiogenic and neurogenic healing signals through NO pathway and VEGF upregulation, accelerating vascular bed formation at repair sites. Its fibroblast-activating properties complement GHK-Cu's direct stimulation of fibroblast collagen synthesis, creating a synergistic two-pronged approach to dermal and soft tissue repair. TB-500 adds systemic actin cytoskeletal support — promoting cellular migration across wound beds, reducing fibrosis, and modulating inflammatory signaling through the PI3K/Akt pathway. Its ability to downregulate TNF-alpha and other pro-inflammatory cytokines helps control the chronic low-grade inflammation that impairs tissue quality in aging skin. The three compounds address aesthetic tissue repair at three levels: the structural scaffold (GHK-Cu collagen stimulation), the vascular supply (BPC-157 angiogenesis), and the cellular migration and inflammation control (TB-500). Research applications include wound healing, post-procedure skin recovery, age-related dermal thinning, and scar tissue remodeling.

Synergy Matrix

Component BPC-157
250mcg twice daily
Component TB-500
2.5mg twice weekly
Component GHK-Cu
2mg daily (Topical or SubQ)

Active Research Thread

Join the ongoing discussion regarding clinical outcomes and anecdotal observations for this protocol.

Discuss in Forum

Clinical Data Matrix

Parameter Clinical Value
Protocol Rank Rank: 11
Optimization Goal Skin & Wound Healing

Clinical Pros

  • Synergistic biological signaling
  • Optimized pharmacokinetic alignment
  • Targeted metabolic pathway focus

Research Limitations

  • Requires precise administration timing
  • Cumulative cost of protocol components
  • Advanced cycle monitoring recommended